Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation, the inhibition of apoptosis, and adhesion and cytoskeleton abnormalities, all of which are characteristics of the disease.
The presence of this gene is a result of the Philadelphia chromosome translocation, which is found in over 90% of chronic myeloid leukemia (CML) cases.
Novartis's BCR-ABL TKI is marketed as Gleevec in the US, and Glivec outside the US for a number of different oncology indications. These include CML, acute lymphoblastic leukemia, and gastrointestinal stromal tumors.
Key Topics Covered:
List of Figures
Figure 1: Gleevec for CML - SWOT analysis
Figure 2: Drug assessment summary of Gleevec for CML
Figure 3: Drug assessment summary of Gleevec for CML
Figure 4: Gleevec - SWOT analysis in acute lymphoblastic leukemia
Figure 5: Drug assessment summary for Gleevec in acute lymphoblastic leukemia
Figure 6: Drug assessment summary for Gleevec in acute lymphoblastic leukemia
List of Tables
Table 1: Gleevec drug profile
Table 2: Gleevec pivotal trial data in CML
Table 3: Gleevec late-phase trial data in CML
Table 4: Gleevec drug profile
Table 5: Pivotal clinical trial data for Gleevec in acute lymphoblastic leukemia
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vcpd59/gleevec?w=4